• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Downloadable tools

      Identifying patients suitable for device-aided therapies: Learnings from clinical experience

      This guide, for UK healthcare professionals, discusses the considerations for selecting an appropriate device-aided therapy (DAT) for people with Complex/Advanced Parkinson’s disease. The considerations featured in this guide are centred on studies of expert opinion based on clinical practice and collective physician perspectives of non-oral medication approaches. Please note, this material does not replace guidelines or locally agreed processes and procedures.

      Virtual Consultations: A quick reference guide

      A quick reference guide on optimising virtual consultations, which contains top tips to support remote management of people with Parkinson’s. The guide includes guidance for before, during and after the consultations, as well as tips to maximise a Parkinson’s specific consultation so you can deliver valuable care.  This guide was developed in collaboration with experts in the field:

      • Dr Jonathan Evans, Consultant Neurologist, Queen’s Medical Centre, Nottingham
      • Ms Miriam Parry, Senior Parkinson’s Disease Nurse Specialist, King’s College Hospital NHS Foundation Trust
      • Ms Katie Goates, Healthcare Relationships Manager, Parkinson’s UK

      Please note: this guide is not intended as a substitute for validated guidelines or locally agreed processes and procedures.

      References

      1. DUODOPA (levodopa/carbidopa intestinal gel) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/medicine/20786. Accessed August 2022.

       

       

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on [email protected] 

       

      UK-DUOD-220171. Date of preparation: August 2022.